Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nat10 modulators for treating or preventing laminopathies, aging and cancer

A lamin, cancer technology, applied in the field of NAT10 modulators for the treatment or prevention of laminopathy, aging and cancer, capable of solving problems such as molecular causes to be determined

Active Publication Date: 2017-05-31
CAMBRIDGE ENTERPRISE LTD +1
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the exact molecular causes of the spectrum of clinical phenotypes associated with laminopathies remain to be determined

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nat10 modulators for treating or preventing laminopathies, aging and cancer
  • Nat10 modulators for treating or preventing laminopathies, aging and cancer
  • Nat10 modulators for treating or preventing laminopathies, aging and cancer

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0138] Compound preparation

[0139] Herein, the term "pharmaceutically acceptable salt" is intended to describe a salt that is not harmful to the patient. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts and pharmaceutically acceptable base addition salts. Acid addition salts include salts of inorganic acids as well as organic acids.

[0140] References to compounds of formula (I) and groups thereof also include, for example, ionic forms, salts, solvates, isomers (including geometric and stereochemical isomers), tautomers, N-oxides as described below , esters, prodrugs, isotopes and protected forms thereof; preferably salts or tautomers or isomers or N-oxides or solvates thereof; more preferably salts or tautomers or N- Oxides or solvates, even more preferably salts or tautomers or solvates thereof. Hereinafter, compounds defined in any aspect of the invention and their ionic forms, salts, solvates, isomers (incl...

Embodiment 1

[0330] Example 1: Rescue of nuclear shape by KAT inhibitors

[0331] Because the lamin protein acts as a scaffold to maintain nuclear structure and anchor chromatin at the nuclear edge (J.Gotzmann, R. Foisner (1999) Crit. Rev. Eukaryot. Gene Expr. 9, 257), so small interfering RNA (siRNA)-mediated depletion of lamin A / C (siLMNA) caused nuclear shape defects in different human cell lines ( figure 1 A, B and figure 2 A, B). Notably, lamin A / C depletion was found to be also associated with overall chromatin relaxation, as observed by enhanced micrococcal nuclease (MNase) sensitivity and increased nuclear area ( figure 1 B, C). Thus, it was reasoned that recompaction of chromatin in lamin A / C depleted cells could ameliorate some of their nuclear structural defects. Lysine acetyltransferase (KAT) and lysine deacetylase (KDAC) have the ability to regulate the acetylation status of histones and other proteins, thus affecting the overall chromatin organization. Therefore, th...

Embodiment 2

[0332] Example 2: Identification of Protein Targets by Chemical Labeling of Compound 2

[0333] To identify putative biological targets of molecular compound 2 and elucidate the mechanism for improved nuclear morphology, a molecular-based strategy was established that included cellular functionalization of the molecule by means of "click chemistry" to find and validate drug-associated protein complexes. To this end, an alkynyl group was strategically introduced into the hydrazone moiety of compound 2, resulting in a Figure 4 B) "clickable" analog compound 3 with equivalent cellular activity ( Figure 4 A), and use an inactive clickable molecule reference compound A as a negative control ( Figure 4 A, B). Although the alkyne moiety is biologically inert, it can react selectively with any molecule bearing an azide group upon copper exposure (V. V. Rostovtsev et al. (2002) Angew. Chem. Int. Ed. Engl. 41, 2596 ), thus allowing the labeling of small molecules in cells ( Fi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to compounds in the treatment or prevention of disorders associated with Lamin A and / or Lamin C depletion or LMNA mutations, such as laminopathy, premature ageing disorders, normal ageing and cancer(such as a cancer characterised by low levels of LMNA expression).

Description

[0001] field of invention [0002] The present invention relates to the treatment or prophylaxis associated with lamin A and / or lamin C depletion or LMNA Compounds for mutation-associated disorders such as laminopathy, progeria, normal aging and cancer. [0003] Background of the invention [0004] The nuclear lamina, composed of A and B-type lamins, maintains nuclear morphology and acts as an anchoring platform for tethering chromatin (T. Dechat et al. (2008) Genes Dev. 22,832). Lamins interact with a variety of chromatin-binding proteins and are also indirectly connected to the cytoskeleton through transmembrane proteins including Nesprin and SUN proteins (M. Crisp et al. (2006) J. Cell Bio. 172, 41 ). encoding lamins A and C LMNA Mutations in β cause a variety of human diseases known as laminopathies (H. J. Worman, G. Bonne (2007) Exp. Cell Res. 313, 2121). These include Emery-Dreifuss muscular dystrophy (AD-EDMD) (G.Bonne et al. (1999) Nat. Genet. 21, 285) and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K8/49A61Q19/08A61K45/06A61K31/426A61K31/549C07D277/50C07D277/60C07D285/16A61P39/06A61P35/00
CPCA61Q19/08A61K45/06A61K31/426A61K31/549C07D277/50C07D277/60A61K8/49C07D285/16A61P1/16A61P17/00A61P21/04A61P35/00A61P39/00A61P39/06A61P43/00A61P9/00A61P3/10
Inventor D.L.D.拉里厄R.J.罗德里格S.F.S.布里顿S.P.杰克森
Owner CAMBRIDGE ENTERPRISE LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com